The anti-inflammatory effects of
statins have likely not been used to their fullest extent, particularly in reducing venous thromboembolic events. Current
therapy for thrombotic events hinges on anticoagulation via
heparin,
warfarin or new oral
anticoagulants. Interventional procedures with
thrombectomy may also play a critical role. Unfortunately, thrombotic events can occur and recur despite meticulous anticoagulation
therapy.
Venous thromboembolism (VTE) includes both
deep vein thrombosis (DVT) and
pulmonary embolism (PE), two complicated and prevalent diseases that can cause
chronic disease states such as post-thrombotic syndrome (PTS). In 2009 the JUPITER trial demonstrated that
rosuvastatin may be effective when dealing with vascular
inflammation by providing an anti-inflammatory effect. Multiple subsequent studies have looked at this association with some promising findings. The mechanism of action for
statins is not entirely understood but there has been a variety of proposals and subsequent testing of inflammatory
biomarkers. Additional prospective trials are needed to confirm the possible benefit of VTE reduction through an anti-inflammatory effect, but if this can be shown then
statins may become a safe adjunctive
therapy for VTE prevention.